Lucas K G, Kiehn T E, Sobeck K A, Armstrong D, Brown A E
Department of Medicine, Memorial-Sloan Kettering Cancer Center, New York, NY 10021.
Medicine (Baltimore). 1994 Jul;73(4):209-14. doi: 10.1097/00005792-199407000-00003.
Previous reports of F. oryzihabitans sepsis involving central venous access devices reveal a relatively high rate of complications, including device removal, despite a course of broad-spectrum anti-microbials with compatible in vitro susceptibility results. In the present report of 22 cases of F. oryzihabitans sepsis treated at Memorial Sloan-Kettering Cancer Center from February 1986 through September 1993, the majority of CVAD-related infections with F. oryzihabitans were successfully treated with a 14-day course of antimicrobials with antipseudomonal activity, and removal of the device was usually not required. Factors that may complicate successful treatment of CVAD-related sepsis caused by F. oryzihabitans include polymicrobial infections and premature discontinuation of antibiotic therapy.
先前有关栖稻假单胞菌败血症累及中心静脉通路装置的报告显示,尽管使用了具有体外药敏结果相符的广谱抗菌药物疗程,但并发症发生率相对较高,包括装置移除。在本报告中,纪念斯隆凯特琳癌症中心于1986年2月至1993年9月治疗了22例栖稻假单胞菌败血症病例,大多数与中心静脉通路装置相关的栖稻假单胞菌感染通过14天具有抗假单胞菌活性的抗菌药物疗程成功治愈,通常无需移除装置。可能使栖稻假单胞菌引起的中心静脉通路装置相关败血症成功治疗复杂化的因素包括多微生物感染和抗生素治疗过早中断。